-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EQS2e1HSy1CgX2pvZ+Emx4m9hDNQtrBCIXy/DlzwRQAgQMWEEapjDSSQ+k/lyftw bo6SFzR4AwgvlEh/9hhX7w== 0000893220-08-002890.txt : 20081105 0000893220-08-002890.hdr.sgml : 20081105 20081105171826 ACCESSION NUMBER: 0000893220-08-002890 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081030 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20081105 DATE AS OF CHANGE: 20081105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDQUIST INC CENTRAL INDEX KEY: 0000884497 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 222531298 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13326 FILM NUMBER: 081164613 BUSINESS ADDRESS: STREET 1: 1000 BISHOPS GATE BLVD STREET 2: SUITE 300 CITY: MOUNT LAUREL STATE: NJ ZIP: 08054-4632 BUSINESS PHONE: 8568108000 MAIL ADDRESS: STREET 1: 1000 BISHOPS GATE BLVD STREET 2: SUITE 300 CITY: MOUNT LAUREL STATE: NJ ZIP: 08054-4632 8-K 1 w71477e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2008
MedQuist Inc.
(Exact name of registrant as specified in charter)
         
New Jersey   0-19941   22-2531298
 
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
     
1000 Bishops Gate Blvd., Suite 300, Mt. Laurel, NJ   08054
 
(address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (856) 206-4000
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
  (b)   R. Scott Bennett, the Senior Vice President of Sales and Marketing of MedQuist Inc. (the “Company”), left the Company to pursue other opportunities effective October 30, 2008.
 
  (c)   The board of directors of the Company has appointed Peter Masanotti, the Chief Executive Officer of the Company, as the President and Chief Executive Officer of the Company effective as of November 3, 2008.
 
      The terms of Mr. Masanotti’s employment with the Company continue to be governed by the employment agreement the Company entered into with him on September 3, 2008 (the “Employment Agreement”).
 
      The current report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2008 is hereby incorporated by reference with respect to the Employment Agreement and other terms of Mr. Masanotti’s employment with the Company discussed therein.

 

 

      There are no transactions in which Mr. Masanotti has an interest requiring disclosure under Item 404(a) of Regulation S-K or any family relationships requiring disclosure under Item 401(d) of Regulation S-K.

 

 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  MEDQUIST INC.
 		  
Date: November 5, 2008  By:   /s/ Mark R. Sullivan    
    Name:   Mark R. Sullivan   
    Title:   General Counsel, Chief Compliance
Officer & Secretary 		  
 

 

-----END PRIVACY-ENHANCED MESSAGE-----